We are now on a new trajectory which every investor should evaluate.
We have just returned from a week long stay in India where we met with Serum Institute (www.seruminstitute.com) at its offices in Pune India. We were invited to meet with Serum’s technical staff and its CEO based on our technology for producing our fully human monoclonal antibody for treating HIV. At the meeting, Serum agreed take our antibody forward through clinical trials – a program that will entail a commitment by Serum of approximately $40 Million.
Who is Serum? Serum is the largest producer of vaccines in the world (not just India, but in the world). It also has an extensive portfolio of monoclonal antibodies that are being developed for treating certain diseases, including rabies, dengue fever and respiratory syncytia (RSV). Thus, Serum is a seasoned participant in the relatively new world of monoclonal antibodies. A dedicated portion of its current biopharma campus in Pune (shown here) is devoted to monoclonal antibodies.
How does all this fit with our technology? Serum openly recognizes that our antibody as one of the most promising in the search for a monoclonal antibody for treating HIV. It also knows that once a successful monoclonal antibody is confirmed, a vaccine can be produced as well. Our technology fits perfectly with its corporate goal and its company expertise. Specifically, we have a proprietary methodology for producing monoclonal antibodies against many diseases – for both humans and for animals. This methodology can be used to produce anti-monoclonal antibodies against a number of diseases effecting humans and animals. http://www.bioclonetics.com/anti-hiv-technology.html.
In the partnership we hope to conclude with Serum, we will complete the confirmation of the molecular sequence of our monoclonal antibody – required for the next step leading to animal and clinical trials. From our sequencing, Serum will produce the recombinant form of the antibody. We will conduct the verification testing of the recombinant and then Serum will conduct animal and then human trials – a $40 Million investment.
Serum’s expertise in the field, its world class production facilities and capability and its belief in our technology make it and its team the perfect partner for us. Serum’s willingness to invest in our technology assures that our technology will have its opportunity to accomplish our goal of providing a worldwide therapy for HIV.
We ask that you share this progress update with your friends and those interested in investment in our technology and its future.
Best regards,
Charles Cotropia
CEO, BioClonetics Immunotherapeutics, Inc.